News
VNDA
6.18
+0.49%
0.03
Vanda Pharmaceuticals Inc <VNDA.OQ> expected to post a loss of 14 cents a share - Earnings Preview
Vanda Pharmaceuticals Inc expected to post a loss of 14 cents a share. The company is expected to report a 13.7% increase in quarterly revenue to $52.383 million. The average analyst estimate for the company is for a 14 cents per share loss.
Reuters · 3d ago
Weekly Report: what happened at VNDA last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at VNDA last week (0708-0712)?
Weekly Report · 07/15 10:19
Vanda Pharmaceuticals Initiated at Overweight by Cantor Fitzgerald
Dow Jones · 07/11 11:37
Vanda Pharmaceuticals Price Target Announced at $11.00/Share by Cantor Fitzgerald
Dow Jones · 07/11 11:37
Cantor Fitzgerald Initiates Coverage On Vanda Pharma with Overweight Rating, Announces Price Target of $11
Benzinga · 07/11 11:27
Weekly Report: what happened at VNDA last week (0701-0705)?
Weekly Report · 07/08 10:20
*Vanda Will Request Relief From Court That Includes Order Requiring Defendants to Discontinue Marketing Generic Versions of HETLIOZ >VNDA
Dow Jones · 07/01 12:09
*Vanda Intends to Proceed With Discovery in the Case to Continue Pursuing Its Claims >VNDA
Dow Jones · 07/01 12:08
*Vanda: Court Concluded Issues of Patentability Weren't Same as Those Resolved in Prior Patent-Infringement Litigation Between Parties >VNDA
Dow Jones · 07/01 12:08
*Vanda: Court Denied Motions for Judgment on Pleadings That Were Filed by Teva Pharmaceuticals USA and Apotex >VNDA
Dow Jones · 07/01 12:07
Weekly Report: what happened at VNDA last week (0624-0628)?
Weekly Report · 07/01 10:20
What's Going On With Vanda Pharmaceuticals Shares Today?
Vanda Pharmaceuticals Inc. Shares are trading lower after Future Pak withdrew its proposal to purchase the company. The company has lost over 9% in the past year. Future Pak said it will focus on other strategic objectives. Vanda rejected Future Pak’s $7.75 per share offer in April.
Benzinga · 06/27 16:10
Vanda Pharmaceuticals drops after Future Pak walks away
Vanda Pharmaceuticals fell 5.3% in premarket trading. Future Pak said it's withdrawing its offer for the company. Vanda rejected two unsolicited buyout proposals last week. The contract manufacturer Future Pak revised its offer to $7.75 per share earlier this month.
Seeking Alpha · 06/27 12:44
Deals of the day-Mergers and acquisitions
UltraTech Cement will buy a 23% stake in rival India Cements for up to $226 million. France's Saint-Gobain agrees to buy Dubai-based construction chemicals company FOSROC. Nokia agrees to sell its submarine business ASN to the French state for $374 million.
Reuters · 06/27 09:51
UPDATE 1-Future Pak withdraws offer to buy Vanda Pharmaceuticals
Future Pak says it has withdrawn its offer to buy U.S. Drugmaker Vanda Pharmaceuticals. The withdrawal comes following a "continued lack of engagement" from Vanda. Future Pak had raised its buyout offer to $9.00 per share earlier this month.
Reuters · 06/26 22:22
FUTURE PAK WITHDRAWS PROPOSAL TO PURCHASE VANDA PHARMACEUTICALS INC.
Reuters · 06/26 21:37
Weekly Report: what happened at VNDA last week (0617-0621)?
Weekly Report · 06/24 10:24
BUZZ-U.S. STOCKS ON THE MOVE-Allstate, MicroStrategy, AutoZone
The S&P 500 and the Nasdaq hit record highs on Thursday. The Dow Jones Industrial Average was up 0.48% at 39,019.33. The top three Nasdaq percentage gainers of the day were Nvidia, Accenture and Gilead Sciences.
Reuters · 06/20 18:00
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Jabil Inc. Fell 7.8% to $116.37 on Thursday. Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down 20.2% year-on-year. MGO Global, Inc. Shares jumped 222.8%.
Benzinga · 06/20 17:26
More
Webull provides a variety of real-time VNDA stock news. You can receive the latest news about Vanda Pharma through multiple platforms. This information may help you make smarter investment decisions.
About VNDA
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).